MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. (INKT) Stock Overview
Explore MiNK Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
253.5M
P/E Ratio
-1.07
EPS (TTM)
$-2.46
ROE
206.54%
INKT Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of MiNK Therapeutics, Inc. (INKT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 58.01, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $2.33.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.07 and a market capitalization of 253.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Jennifer S. Buell
23
149 Fifth Avenue, New York City, NY
2021